Actinogen Targets Mid-November for Xanamem Alzheimer's Trial Results

Bitget2026/10/28 12:51

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Actinogen Medical narrowed guidance for final XanaMIA Alzheimer’s trial topline results to mid-November 2026, from November, following database lock.
The randomized, double-blind phase 2b/3 trial compares oral Xanamem 10 mg with placebo over 36 weeks.
Enrollment totaled 247 participants across Australia and the United States, selected for elevated plasma pTau181.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinogen Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280851PRIMZONEFULLFEED9855051) on October 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Actinogen Targets Mid-November for Xanamem Alzheimer's Trial Results

You may also like

Crypto prices